Kymera Results Presentation Deck

KT-474 Phase 1 Trial Design Double-blind, placebo-controlled SAD and MAD in Adult HV; Open Label Patient Cohort in HS & AD Patients Parts A & B Healthy Volunteers (HV) SAD and MAD Todays' Focus Part C HS and AD Patients 9 SAD cohorts - 8 subjects per cohort (6:2 randomization) including 2 food-effect cohorts - 72 adult healthy subjects dosed Single dose (25-1600 mg) 5 MAD cohorts - 12 subjects per cohort (9:3 randomization) 60 adult healthy subjects dosed 14x daily doses (25-200 mg, MAD 1-4); 5x twice-weekly doses (200 mg, MAD5) - 1 cohort 21 HS and AD patients 75 mg (fed state) (~equivalent exposure to 100mg fasted MAD cohort dose level) Open-label 28x daily doses KYMERA ©2022 KYMERA THERAPEUTICS, INC. ● ● ● ● Summary of Key Findings in MAD IRAK4 degradation of 80-90% in PBMC using Flow Cytometry; reduction to near lower limit of quantification with Mass Spectrometry Associated with up to 85% inhibition of multiple disease-relevant cytokines and chemokines in ex vivo TLR stimulation assay at 100 mg dose Dose-dependent IRAK4 degradation in skin of >50% Generally well tolerated at doses up to 200 mg with no SAEs Non-adverse, self-limiting QTcF prolongation in 10-20 msec range was neither dose- nor exposure-dependent Primary Secondary/ Exploratory ● Safety & tolerability Pharmacokinetic measures (half-life, bioavailability) IRAK4 knockdown in PBMC and skin Change in systemic inflammatory biomarkers and proinflammatory gene transcripts in skin Ex vivo response of whole blood to TLR agonists Clinical endpoints: EASI (AD), Total AN Count (HS), symptom scores and global assessments PAGE 27

View entire presentation